α_2-肾上腺素能激动剂—阿法根缩瞳作用的临床研究进展  

Clinical advance of miotic effect of α2-adrenergic agonist-Alphagan on pupil size

作　　者：张磊[1] 顾欣祖[1] 

机构地区：[1]中山大学中山眼科中心神经眼科,中国广东省广州市510060

出　　处：《国际眼科杂志》2006年第1期145-148,共4页International Eye Science

基　　金：中国国家自然科学基金资助项目(No30471847;30171003)

摘　　要：Brimonidine(阿法根)是第三代高度选择性α2-肾上腺素能激动剂,2000年进入我国作为治疗青光眼的药物。在早期对brimonidine的研究中,是以眼压为主要观察指标,没有注重其对瞳孔的作用,并指出brimonidine对瞳孔无显著性影响。而近年来,不少研究表明brimonidine对瞳孔有着显著的缩瞳作用,使其具有了新的临床应用方向。现就这一方面,对近年来的研究进行综述。Alphagan, α highly selective α2 adrenergic receptor agonist, has been used as an antiglaucoma drug in China from the year of 2000. In the early research on Brimonidine, the intraocular pressure CIOP） was the primary focus but not the pupils, and no eafect of Brimonidine on pupil size was found. Recently, many studies showed that Brimonidine has significant miotic effect on pupil size and a new clinical application has been found. This paper reviews the research on the miotic effect of Brimonidine in recent years.

关 键 词：酒石酸溴莫尼定 瞳孔 缩小 

分 类 号：R775[医药卫生—眼科]